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THE EFFECT OF PERSISTENT HIGH BLOOD GLUCOSE 
ON INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE 
GRACE GOODFELLOW 
ABSTRACT 
Background: The prevalence of Alzheimer’s disease (AD) and other types of dementia is 
expected to drastically increase between now and midcentury because of the aging baby 
boomer population. It is projected that by 2030, 74 million people aged 65 and older will 
comprise nearly 20% of the population (United States Census Bureau, 2017). By 2060, it 
is estimated that about 13.8 million people will have AD. In 2020, the estimated total 
health care costs for treating individuals with AD in 2020 is $305 billion (Wong, 2020). 
As the population ages, the cost is expected to increase to more than $1 trillion. This 
significant economic and health care burden could be greatly alleviated by the 
development of a treatment that would delay the onset of the disease or prevent the 
disease altogether. Increasing evidence supports cardiovascular health being linked to the 
health of the brain. Type II diabetes mellitus (T2DM) is a particular risk factor that 
increases the likelihood of cardiovascular disease and is consequently associated with a 
higher risk of developing AD and other dementias.  
Aim: The aim of this study was to determine the association between persistent high 




Methods: This study included 1287 Framingham Offspring participants (669 women, 
mean age 68.6 ± 5.7 years) who were free of dementia and attended 5 consecutive 
examinations at 4-year intervals starting at midlife (Exam 3: 1983–1987, mean age 54.6 ± 
5.8 years) until late life (Exam 7: 1998–2001, mean age 68.6 ± 5.7 years). These 
participants were subsequently followed up for incident dementia after a period of time 
(mean 14 ± 4.5 years). Based on the resulting data, this study examined the effect of 
midlife T2DM (fasting blood glucose level ≥ 126 mg/dL), late-life T2DM, 10-mg/dL 
incremental increases in fasting blood glucose (FBG), persistence of T2DM during 
midlife to late life, and a steep increase in FBG from midlife to late life over an 18-year 
exposure period. Further stratified analysis was completed on a subgroup of participants 
with a steep incline in FBG to determine if there was an interaction effect with 
apolipoprotein E4 (APOE4) carrier status. 
Results: During the follow-up period, 172 participants developed dementia, and of these 
cases, 135 participants had AD. Multivariable Cox proportional hazards models showed 
that persistent high FBG was associated with greater than 2-fold increase in risk of both 
incident dementia (hazard ratio [HR] 2.13, 95% confidence interval [CI] 1.37-3.33) and 
AD ([HR] 2.18, 95% [CI] 1.33-3.57) after adjusting for age, sex, education, APOE4, 
prevalent cardiovascular disease (CVD), and midlife T2DM treatment. In addition, 
individuals who experienced a steep increase in their FBG from Exam 3 to Exam 7 were 




stratification by APOE4 carrier status with a steep increase in FBG revealed that APOE4 
non-carriers were associated with an approximate 2-fold increased risk for developing 
incident dementia ([HR] 1.90, 95% [CI] 1.12-3.16; p value < 0.05) and AD ([HR] 2.30, 
95% [CI] 1.28-4.06; p value < 0.05). 
Conclusions: Persistent high blood glucose was associated with an increased risk for 
developing incident dementia and AD in a community-based cohort. A steep increase in 
FBG during midlife to late life also increased the risk for developing dementia and AD in 
this cohort. These data support the potential of sustained cognitive benefits from lower 
blood glucose levels in midlife but also suggest that sharp increases in blood glucose 
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Alzheimer’s Disease and Dementia 
Alzheimer’s disease (AD) and other forms of dementia are presently debilitating 
the lives of 50 million people worldwide (Alzheimer’s Association, 2021a). AD accounts 
for the majority of these cases, roughly 60%-70% (“The Need for Early Detection and 
Treatment in Alzheimer’s Disease,” 2016). The prevalence of dementia is rapidly 
expanding, and it is estimated that by the year 2050, 12.7 million people in the United 
States aged 65 and older will be living with AD (Gaugler et al., 2021). This increase is 
due to a widespread aging population and the lack of an effective treatment. 
Approximately two-thirds of Americans living with AD are women. Out of the 6.2 
million people aged 65 and older with AD in the United States, 3.8 million are women 
and 2.4 million are men (Rajan et al., in press). A potential reason why more women have 
AD and other dementias than men could be due to the fact that women tend to have 
longer life expectancies, and older age is the greatest risk factor for AD. However, the 
incidence risk (the risk of actually developing AD or other dementias) between men and 
women may be more comparable. In the United States, most studies have found that there 
is no difference in the incidence risk between men and women in the proportion of 
individuals who develop AD or other dementias at any age (Chêne et al., 2015; Gaugler 
et al., 2021). There do not appear to be differences in the rate at which men and women 
develop AD or other dementias; however, there may be different pathologies behind why 




in chromosomes and/or hormones), in environmental, social, or cultural origins (e.g., 
gender differences), or a combination of the two (Mielke et al., 2018). 
AD is clinically characterized by progressive memory loss and a gradual decline 
in cognitive function, leading to premature death usually occurring about 3-9 years after 
diagnosis (Li et al., 2015). More severe stages, with progressive deficits, occur mostly in 
older individuals (>65 years of age) (Biessels & Despa, 2018). The ultimate etiology of 
AD remains unknown. The “amyloid cascade hypothesis” is the most widely supported 
description of the pathophysiology behind AD (Barage & Sonawane, 2015). This 
hypothesis postulates that the neurodegeneration in AD is caused by abnormal 
accumulation of extracellular senile plaques containing amyloid-β (Aβ) protein, as a 
result of improper proteolytic processing of Amyloid Precursor Protein (APP) (Rabbito et 
al., 2020). These plaques form in areas of the brain that are responsible for cognition and 
memory. The second most common neuropathological component underlying the disease 
involves the presence of intracellular neurofibrillary tangles (NFTs). NFTs consist of 
hyperphosphorylated tau proteins, which impair microtubule function, axonal transport 
and cause breakdown of the cytoskeleton. The formation of both Aβ plaques and NFTs 
ultimately results in a substantial loss of neurons and synapses. 
AD may either have an early onset, between 40 and 65 years of age, or more 
commonly, late onset, occurring after the age of 65 (Rabbito et al., 2020). AD is further 
divided into sporadic AD (SAD) and familial AD (FAD) (Liu et al., 2019). SAD and 
FAD do not differ in clinical presentation. FAD accounts for 1-5% of all AD cases. 




(PSEN2) are involved in FAD- along with the ε4 allele of apolipoprotein E (APOE4). 
SAD, accounting for more than 95% of all AD cases, is believed to arise from various 
genetic and environmental risk factors that have not yet been fully elucidated. 
As AD and other forms of dementia progress, individuals require increasing levels 
of medical care and support, leading to a substantial economic burden (Deb et al., 2017). 
In a population-based study involving participants aged 70 to 89, annual health care costs 
were greater for those with dementia than for those with less advanced forms of cognitive 
impairment (Leibson et al., 2015). People with AD and other forms of dementia who also 
have comorbidities, such as coronary artery disease, T2DM, chronic kidney disease, 
chronic obstructive pulmonary disease, stroke, or dementia, have higher use and costs of 
health care than people with these medical conditions but without AD or dementia 
(Gaugler et al., 2021). Total costs for health care, long-term care, and hospice care for 
people with AD and other dementias are expected to increase from $355 billion in 2021 
to more than $1.1 trillion in 2050. These costs include both government spending under 
Medicare and Medicaid and out-of-pocket spending (Gaugler et al., 2021). Identification 
of a treatment that can either delay the onset of dementia or reduce the symptoms would 
significantly benefit individuals, as well as drastically reduce health care spending. One 
study estimated that if a treatment delaying the onset of AD by five years were to be 
introduced by 2025, total health care payments would be reduced by 33% and out-of-





Progression of AD 
AD progresses along a biological and clinical continuum, starting with the 
preclinical phase. The second broad phase is mild cognitive impairment (MCI) due to 
AD, followed by dementia due to AD. The AD dementia phase is further broken down 
into mild, moderate, and severe, with each stage reflecting the degree to which the 
disease interferes with an individual’s ability to carry out everyday activities (Gaugler et 
al., 2021). These changes occur in a sequential but overlapping manner. 
Beginning with an asymptomatic phase, AD progresses through a long preclinical 
period in which pathophysiological changes occur along with increasing biomarker 
evidence of disease. Examples of these biomarkers include abnormal levels of amyloid-β 
(Aβ) protein, as shown on positron emission tomography (PET) scans and in analysis of 
cerebrospinal fluid (CSF), and decreased metabolism of glucose, as shown on PET scans 
(Sperling et al., 2020). Eventually, cognitive and functional impairments become 
increasingly apparent. This is the clinical (symptomatic) phase of AD (Aisen et al., 
2017). 
MCI due to AD initiates the symptomatic phase which is characterized by subtle 
cognitive changes that do not interfere with everyday activities. Among these individuals, 
about 15% develop AD within two years and about 32% develop AD within five years 
(Peterson et al., 2018). Some individuals are diagnosed with MCI several years after the 
beginning of their cognitive decline, so they are likely to develop dementia sooner than 




to more advanced stages and may even revert to having normal cognition (Gaugler et al., 
2021). 
Dementia due to AD is characterized by noticeable memory, thinking, or 
behavioral symptoms that inhibit an individual from being able to function in daily life, 
combined with biomarker evidence of AD-related pathology. In the mild stage of AD, 
individuals still maintain most of their independence but require some assistance with 
certain activities. In the moderate stage, individuals begin to have difficulty 
communicating and performing daily tasks. They may also start experiencing behavioral 
and personality changes. This is often the longest-lasting stage of AD. In the severe stage 
of AD, individuals require assistance with all activities and usually need around-the-clock 
care. Their physical health becomes most prominently affected during this stage, and 
individuals often become bedbound. Consequently, these individuals become vulnerable 
to other medical issues such as bed sores, skin infections, sepsis, and blood clots (Gaugler 
et al., 2021). The length of each phase along the continuum varies from person to person 
and is influenced by age, genetics, biological sex, and other factors (Vermunt et al., 
2019). After clinical diagnosis of AD, the mean life expectancy is approximately seven 
years with only 3% of people living more than 14 years longer (Khan & Alkon, 2015).  
 
APOE4 Genotype 
The best-known genetic risk factor for AD is APOE4 (Yamazaki et al., 2019). 
APOE4 carrier status interacts synergistically with T2DM, causing cognitive decline in 




risk of both AD and vascular dementia when compared to T2DM without the APOE4 
allele. 
Research suggests that the APOE4 allele inhibits Aβ protein clearance and 
promotes its aggregation. APOE4 also contributes to the pathogenesis of AD by 
impairing microglial responsiveness, lipid transport, synaptic integrity and plasticity, 
glucose metabolism, and cerebrovascular integrity and function (Yamazaki et al., 2019). 
These problems all lead to neurodegeneration and eventual development of AD and other 
dementias. APOE4 influences the timing and amount of amyloid deposition in the brain 
by increasing the neurotoxicity of Aβ (Liu et al., 2019). 
 
Mixed Dementia 
Mixed dementia is a condition in which multiple types of dementia occur 
simultaneously. Most commonly, AD is accompanied by vascular dementia. Cognitive 
impairment of vascular etiology is the second most prevalent form of dementia. Changes 
of the small and large cerebral vasculature, including the microcirculation of the 
subcortical white matter, cause similar cognitive dysfunction and clinical expression as 
AD (Iadecola et al., 2019). The combination of pathologies from different types of 
dementias increases the chance for clinical presentation of dementia symptoms (Gaugler 
et al., 2021). Studies have shown that the majority of people who have AD also have a 
second form of dementia. One particular autopsy study examined 447 people who had 
AD when they died (Kapasi et al., 2017). Of these people, 3% had brain changes 




82% had brain pathologies of AD and at least one other type of dementia. Mixed 
dementia is especially common at advanced ages (Gaugler et al., 2021). It is important to 
note, however, that the presence of these brain pathologies does not always translate to 
dementia diagnosis. These pathologies may be present without clinical expression. 
Therefore, neuropathologists will only make a diagnosis of low, medium, or high 
likelihood of AD. 
AD and other forms of dementia, like many other chronic diseases, develop as the 
result of multiple potential causes. Aside from age, genetics, and family history, there are 
some risk factors that can be controlled to a certain extent to reduce the risk of cognitive 
decline and dementia. Many of these modifiable risk factors affect cardiovascular health 
which directly affects brain health. T2DM is a particular risk factor that has been the 
focus of many recent studies (Gaugler et al., 2021). 
 
Type II Diabetes Mellitus 
The global prevalence of T2DM is rapidly increasing (Khan et al., 2019). In 2017, 
approximately 6.28% of the world’s population (about 462 million individuals) were 
affected by T2DM, corresponding to a prevalence rate of 6059 cases per 100,000 people. 
Recognized globally as the ninth leading cause of death, T2DM is attributed to over one 
million deaths per year. By 2030, the global prevalence of T2DM is expected to rise to 
7079 cases per 100,000 individuals.  
A correlation between T2DM and AD was first reported in the large population-




consistently identified as a modifiable risk factor for cerebrovascular pathology, which 
ultimately leads to stroke and various forms of dementia, including AD (Vijayan & 
Reddy, 2016). T2DM increases the long-term risk of developing dementia by nearly two-
fold and one in ten cases in the world population may be attributable to the effects of 
T2DM (Tumminia et al., 2018). A multisystem disorder affecting the pancreas, muscle 
tissue, liver, fat cells, kidneys, and brain (Brunton, 2016), T2DM is characterized by 
hyperglycemia, insulin resistance, and loss of pancreatic β‐cell function (Chornenkyy et 
al., 2019). High blood glucose may be a result of insulin resistance in which the body 
becomes unresponsive to insulin, a hormone that enables glucose to move into cells and 
fuel vital processes. The body responds by overproducing insulin to maximize energy 
production until it reaches a maximum amount. As cells become more insulin resistant, 
blood glucose levels continue to rise, resulting in the development of T2DM. 
Decreased brain glucose uptake and impaired glucose metabolism are associated 
with AD (Yin et al., 2016). High glucose levels in brain tissue are associated with 
increased severity of Aβ aggregation and NFT presence (An et al., 2017). T2DM causes 
accelerated aging, leading to premature morbidity and mortality (Pugazhenthi et al., 
2017). Impaired insulin sensitivity, Aβ accumulation, tau hyperphosphorylation, vascular 
damage and inflammation are some of the shared pathologies between AD and T2DM 
(Tumminia et al., 2018). In addition to these, people with T2DM have abnormally 
processed islet amyloid polypeptides in their pancreases that are similar to the APP 




Numerous previous epidemiological studies have supported this association 
between T2DM and an increased risk for developing AD. One particular recent study 
found that T2DM in an elderly Chinese population with MCI influences the progression 
to AD, while no change was observed in the age-matched control group (Li et al., 2016). 
T2DM increases the risk of heart disease, stroke and various forms of dementia by 
damaging cerebral vasculature (Hayden, 2019). Damaged blood vessels in the brain may 
contribute to the development of AD. High blood glucose levels may damage brain cells 
by causing inflammation, which also increases the risk for developing AD. However, the 
exact clinical mechanism behind this relationship is still unknown. 
In addition, T2DM also affects the synthesis and release of certain 
neurotransmitters that may impair cognition (Chatterjee & Mudher, 2018). Under chronic 
hyperglycemia, extracellular brain levels of gamma-aminobutyric acid (GABA) and 
glutamate were decreased in streptozotocin-induced diabetic animal models (van Bussel, 
et al., 2016). An imbalance between these inhibitory and excitatory neurotransmitters 
resulted in cognitive deficits in these animals.  
Neurogenesis has been shown to be altered in the diabetic brain. Neurogenesis 
involves the proliferation of neuroprogenitor cells (NPCs) and their differentiation into 
neurons, astrocytes and oligodendrocytes (Pugazhenthi et al., 2017). Animal models of 
T2DM, such as the Goto-Kakizaki rat (a genetic model for T2DM), have shown impaired 
neurogenesis and a decrease in NPC survival. A recent study showed that when NPCs 
differentiate after exposure to different cytokines, including interleukin (IL)-1β, tumor 




NPCs differentiate into a glial phenotype (Qin et al., 2016). This suggests that elevated 
circulating cytokines from T2DM can alter neurogenesis in the brain. These cytokines are 
responsible for hormonal regulation of glucose metabolism (Kubis-Kubiak et al., 2020). 
T2DM has also been found to decrease the threshold of the amount of Aβ aggregation 
needed for the manifestation of dementia (Pugazhenthi et al., 2017). The association of 
T2DM with AD is likely to be more apparent in the future since the life expectancy of 
people with T2DM is increasing due to the availability of a wider range of drugs for 
managing T2DM. 
 
Type III Diabetes Mellitus 
With the increasing number of recent studies indicating T2DM as a risk factor for 
developing AD, some have called AD the “diabetes of the brain” or type III diabetes 
mellitus (T3DM) (Nguyen et al., 2020). T3DM manifests as insulin resistance within the 
brain, contributing to the etiology of AD. AD is the sixth leading cause of death in the 
United States and the fifth leading cause of mortality in people 65 and older. Not far 
behind, T2DM is the seventh leading cause of mortality and is estimated to affect about 
half a billion people by 2045 (Saeedi et al., 2019). Both AD and T2DM have been 
recognized as being caused by multifactorial interactions between the environment and 
genetics. Insulin insensitivity has been linked to memory deficits, cognitive decline, and 
other characteristic symptoms that are also observed in AD. T2DM has remained one of 




suggest that insulin resistance increases the risk for dementia and AD in nondiabetic 
populations as well (Nguyen et al., 2020). 
Scientists have recently identified T3DM as a metabolic syndrome that could lead 
to abnormalities linked to progressive brain insulin resistance, impairment of central 
insulin signaling processes, accumulation of neurotoxins, and neuronal stress (Nguyen et 
al., 2020).  This ultimately results in extensive neurodegeneration and cognitive decline 
as seen in patients with dementia. 
 
Insulin Resistance and Pathogenesis of AD 
Insulin-signaling dysregulation may be a critical early contributing factor in AD 
pathogenesis (Tumminia et al, 2018). Insulin is a hormone that is produced by the beta 
cells of the islets of Langerhans in the pancreas and consists of two polypeptide chains 
connected by disulfide linkages (Weinstein et al., 2019). This hormone regulates glucose 
levels in the blood by binding to transmembrane glycoprotein receptors formed by two α- 
and two β-subunits. Insulin is involved in the expansion and preservation of excitatory 
synapses and dendritic spine formation, which are integral to insulin signaling. This 
hormone also mediates cell survival by modulating apoptotic (cell death) pathways and 
the intermediates involved in the apoptotic cascade (Nguyen et al., 2020). 
Insulin resistance (IR) contributes to the development of AD through multiple 
different pathways. Impaired hippocampus insulin signaling disrupts memory processing 
and other executive functions (Nguyen et al., 2020). This contributes to the decline of 




resistance decreases insulin signaling in the central nervous system, resulting in alteration 
in brain metabolism. Increased Aβ toxicity, tau hyperphosphorylation, oxidative stress, 
and neuroinflammation are attributed to central insulin resistance and lead to 
neurodegeneration. Both the processing of Aβ precursor protein toxicity and the 
clearance of Aβ are attributed to impaired insulin signaling in the brain, and this forms 
the basis of linking T3DM and AD. When the neuronal insulin receptor in the brain 
becomes desensitized in insulin resistance, T3DM occurs, ultimately leading to AD.  
IR in the brain with oxidative stress and neuroinflammation may cause Aβ 
accumulation, a significant morphological characteristic of AD (Gabbouj et al., 2019). 
Previous studies have shown that insulin stimulation may increase or accelerate 
trafficking of Aβ from the Golgi network to the plasma membrane of the cell. Therefore, 
insulin may activate Aβ extracellular excretion while also inhibiting its intracellular 
accumulation, and this situation can lead to a significant increase in extracellular Aβ 
accumulation. Both T2DM and AD patients have similar Aβ deposits in the pancreas and 
the brain (Nguyen et al., 2020). Dysfunctional insulin signaling pathways create a state of 
hypometabolism as seen in both AD and T2DM. The malfunctioning insulin pathways 
and resistance of insulin are the result of receptor dysfunction, altered receptor 
expression, changes in receptor binding and the phosphorylation chain, or altered 
activities related to kinases involved in phosphorylation (Nguyen et al., 2020). 
Various studies have supported the shared pathology of IR between T2DM and 
AD (Jayaraj et al., 2020). Metabolic disorders, such as T2DM, obesity, and hypertension, 




recruited participants from the Metabolic Syndrome in Men (METSIM) study to evaluate 
the presence of specific biomarkers from these individuals that could potentially detect 
the risk of developing AD (Westwood et al., 2017). Researchers specifically analyzed the 
influence of IR on plasma and CSF AD biomarkers in 28 IR and 30 non-IR Finnish men 
with metabolic disorders. CSF AD biomarkers, including total tau, phosphorylated tau, 
and Aβ were quantified with respect to IR. No differences were observed in CSF AD 
biomarkers between IR and non-IR groups, but plasma insulin correlated with CSF Aβ 
and tau levels in the whole cohort, with 487 plasma and 200 CSF proteins differentially 
expressed across these groups. In conclusion, this study found that IR is not directly 
related to level of CSF AD biomarkers in cognitively healthy men.  
 
Current Treatments for AD and Other Dementias 
There are currently no effective treatments for AD and other dementias that are 
able to slow or stop the destruction of neurons. There are only five approved medications 
that are able to temporarily attenuate progression of symptoms. Many factors contribute 
to the complexity of developing an effective treatment for AD, including the slow pace of 
recruiting sufficient numbers and diversity of participants to clinical studies, the gaps in 
knowledge about the precise molecular changes and biological processes in the brain that 
cause Alzheimer’s disease, and the relatively long time needed to observe whether an 
investigational treatment affects disease progression. In addition, mixed dementia is 
comprised of multiple different pathological processes, making it extremely difficult to 




related therapeutics have been suggested to succeed in the development of treatments for 
AD by slowing down the progressive nature or potentially preventing future 
complications (Nguyen et al., 2020). 
Diet is one significant lifestyle changes that one can make to prevent T2DM and 
ultimately AD and other dementias. Fruits and vegetables have anti-inflammatory 
benefits and serve as antioxidants. Animal studies have recognized fruits and vegetables 
as protective against cognitive and brain neuropathology from dietary oxidative stress 
due to bioactive substances such as carotenoids, antioxidant vitamins, polyphenols, and 
flavonoids (Van Giau et al., 2018). Diets rich in omega-3 fatty acids and naturally low in 
omega-6 fatty acids may also have potential for nutritional therapy for AD patients. The 
ketogenic diet (low-carbohydrate and high-fat intake) may be able to clear Aβ plaques 
and reduce inflammation. Recent research has shown that glycated APOE4 protein and 
dysfunctional insulin signaling pathways lead to impaired energy transport for brain 
tissues as well as impaired lipid transportation, mainly cholesterol (Van Giau et al., 
2018). Approximately 20% of the general population have the APOE4 gene, and this 
increases to >50% among people with AD. The APOE4 gene and the peripheral insulin 
resistance caused by a high-fat diet further induce insulin resistance in the brain. The 
APOE4 protein binds more aggressively to insulin receptors on the surfaces of neurons 
than its normal counterpart, apolipoprotein E3 (APOE3). After blocking the insulin 
receptor, the APOE4 protein aggregates and becomes toxic, preventing brain cells from 




Exercise is another significant modifiable risk factor that can have profound 
effects on a person’s cognitive state and overall health. This activity is preventative 
against obesity, T2DM, AD, and many other diseases. Exercise increases neurochemical 
messaging within the brain, protects against insulin resistance, and even has the ability to 
clear Aβ plaques in some individuals (Nguyen et al., 2020). One particular study, called 
the “FINGER Study,” examined 1200 participants who had an increased risk for 
cognitive decline (Ngandu et al., 2015). The results from this large, two-year, randomized 
control trial demonstrated that a multifaceted intervention plan including diet, exercise, 
cognitive training, and monitoring vascular risk factors can improve or maintain 
cognitive functioning in older individuals (aged 60-77) from the general population at 
risk of dementia. 
The complexity of AD and other forms of dementia demands the potential for 
combination therapy to address the various biological pathways that are affected. Current 
approved treatments for AD are limited to cholinesterase inhibitors and memantine or the 
combination of these agents (Cummings et al., 2019). They have a moderate impact by 
delaying progression of the disease by only 6-12 months. Many recent drugs being 
studied have failed larger phase III clinical trials because they do not meet efficacy 
endpoints. The high failure rate of the therapies in development for AD may, in part, be 
due to the varying pathologic causes of the disease as well as an incomplete 
understanding of the relationships among the numerous pathways involved in 




Implementing effective prevention strategies is very complex because it requires 
identification, characterization, and participation of asymptomatic individuals, 
development of new primary endpoints, implementation of AD biomarkers in cognitively 
healthy people, disclosure of results, and performance of long trials with yet to be 
identified optimal length. The use of biomarkers to identify individuals at risk of 
developing AD dementia can help to more readily find ideal candidates to participate in 
trials and secondary prevention initiatives. Clinical trials should aim to focus on the 
preclinical stage of AD to maximize treatment outcomes before the disease has 
progressed too far. This also increases the possibility of obtaining a clinical signal as well 
as developing sensitive methods for detecting early decline through new trial designs 
(Crous-Bou et al., 2017). Identifying modifiable risk factors earlier in life can mediate 
potential future risk of AD. This is a powerful prevention strategy, and given its 
prevalence in mid-life, T2DM management provides a potential avenue to prevent AD 







T2DM has been consistently been identified as a risk factor for developing AD and other 
types of dementias. Further research is needed to investigate the effects of chronic 
exposure to elevated blood glucose levels (BGL). It is unknown whether the devastating 
impact of T2DM is due to persistent high BGLs or to exposure at any point during life. 
This study aims to elucidate the association between persistent high blood glucose during 
midlife to late life and the risk of incident dementia and AD. To achieve this aim, this 
study will analyze the effect of midlife T2DM (fasting blood glucose level ≥ 126 mg/dL), 
late-life diabetes, 10-mg/dL incremental increases in fasting blood glucose (FBG), 
persistence of T2DM during midlife to late life, and a steep increase in FBG from midlife 
to late life over an 18-year exposure period. This study also aims to address whether there 
is an interaction effect between having a steep increase in FBG with an apolipoprotein E4 
(APOE4) genotype. It is hypothesized that persistent high blood glucose and a steep 
increase in FBG from midlife to late life associated with an APOE4 genotype will 









Study Population and Eligibility 
To determine the effect of persistent high blood glucose on incident dementia and 
Alzheimer’s disease, this investigation used data previously collected from the 
Framingham Heart Study (FHS) Offspring cohort. At the time of recruitment (1971-
1975), the Framingham Offspring participants were a large, middle-aged, community-
based cohort that had been longitudinally followed up for cardiovascular risk factors and 
occurrence of stroke, cognitive decline, and dementia for over 40 years. Participants were 
examined every four years beginning from their date of entry into the study. Participants 
in the Offspring cohort who attended a minimum of 5 sequential examinations starting at 
midlife (Exam 3 [1983–1987], mean age 55 years) and continuing into later life (Exam 7 
[1998–2001], mean age 69 years) and who were ≥60 years and without a diagnosis of 
dementia (based on ongoing surveillance) at the time of Exam 7 were included in this 









Flow of Cohort Participants Until 2018 
 
 
Note. This figure shows how participants in this study were selected based on whether 
they attended all Exams and if they were dementia-free by Exam 7 and if they were ≥60 
years old. It also shows when FBG measurements were taken and how many participants 









Standard Protocol Approvals, Registrations, and Patient Consents 
Written informed consent was obtained from each participant. The Institutional 
Review Board of the Boston University Medical Campus and the Boston Medical Center 
approved all study protocols and consent forms. 
 
Blood Glucose Level and T2DM Diagnosis 
BGL was recorded in a consistent manner during each examination cycle. T2DM 
was diagnosed as having a non-fasting plasma glucose ≥ 200 mg/dL (≥11.1 mmol/L), a 
fasting blood glucose (FBG) of 126 mg/dL (7 mmol/L) or higher on two separate tests, a 
reading of 200 mg/dL (11.1 mmol/L) or higher after a two-hour post oral glucose 
tolerance test, or documented use of insulin or an oral hypoglycemic drug. The FHS 
measured FBG levels at the time of each exam to determine persistent high BGL. 
Persistent high FBG was defined as any two measurements ≥ 126 mg/dL of five fasting 
blood glucose measurements from Exam 3 to Exam 7. A steep increase in FBG was 
based on a cutoff score of slope 2 mg/dL per year (a steep increase in fasting glucose 
during midlife to late life). 
 
Outcome Measures 
The primary outcome measure was incident dementia developing at any time after 




Dementia was diagnosed according to the criteria of the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV), requiring impairment in memory 
and at least one other domain of cognitive function along with documented functional 
disability (American Psychiatric Association, 1994). In the coding manual used for this 
study (Table 1), participants with dementia were rated using diagnosis variables of 1-8 
and 10. AD was diagnosed when participants met the criteria of the National Institute of 
Neurologic and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association for definite, probable, or possible AD (Mckhann et al., 
2011). In the coding manual for dementia and AD (Table 1), participants with AD were 
rated using diagnosis variables of 1, 2, and 4. 
 
Table 1 
Coding Manual for Dementia and AD 
Code or Value Description 
0 None 
1 Alzheimer’s disease without stroke 
2 Alzheimer’s disease with stroke 
3 Vascular dementia without Alzheimer’s disease 
4 Mixed dementia type (Alzheimer’s disease & vascular dementia) 
5 Frontotemporal dementia 
6 Dementia with Lewy bodies 
7 Dementia that does not fit any other category (progressive) 
8 Dementia that does not fit any other category (nonprogressive) 
9 Cognitive impairment (no dementia) 
10 Dementia (uncertain) 
. Unknown 
 
Note. This table shows the code assigned to each different diagnosis. Retrieved from 





Beginning with Offspring Exam 5, participants were systematically screened for 
the occurrence of dementia. At Offspring Exams 7–9, all participants were also given the 
opportunity to complete a 45-minute neuropsychological battery test and a brain 
magnetic resonance imaging (MRI) scan. If any concern for cognitive impairment was 
raised by the participant, a family member, or a Framingham study staff or physician or if 
the Mini-Mental State Examination score was below an education-based cutoff (3 points 
lower than the preceding examination or 5 points lower than the participant’s highest 
recorded score), more in-depth cognitive testing was performed (Arevalo-Rodriguez et 
al., 2015). Participants with suspected cognitive impairment that did not meet diagnostic 
criteria for dementia were invited for additional neuropsychological assessments which 
were given on average every 1-2 years between the scheduled Offspring examinations. 
The final diagnosis and date of diagnosis of dementia were established after a review of 
all available (1) neurologic examination records, (2) neuropsychological assessments, (3) 
study records, (4) hospital, nursing home, and outpatient clinic records, and (5) family 
interview information by a committee that included at least one neurologist and one 
neuropsychologist. AD was diagnosed when participants met the criteria of the National 
Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer’s 









Adjustments were made for demographics and baseline covariates (measured at 
Exam 7) including age, sex, education, APOE4, prevalent cardiovascular disease (CVD), 
and midlife T2DM treatment. Self-reported use of T2DM treatment was recorded and 
verified by the Framingham Heart Study researchers and consensus panel. Treatment 
included the use of an oral hypoglycemic agent or insulin. 
 
Statistical Analysis 
Multivariable-adjusted Cox proportional hazards models were utilized to 
determine the effect of T2DM (FBG level ≥ 126 mg/dL) and FBG (per 10-mg/dL 
increment) during midlife and late life. The effects of persistent high FBG during midlife 
to late life and a steep increase in FBG from midlife to late life over an 18-year exposure 
period were also determined. The slope of FBG for each individual across all five 
examinations was calculated using a person-specific linear regression model, and this 
intra-individual slope was then related to risk of subsequent dementia. A threshold effect 
was observed at the 88% quartile of FBG slope, slope ≥ 2.0 mg/dL/y (i.e., the steepest 
increase in FBG from midlife to late life). Multivariable-adjusted Cox proportional 
hazards models were generated to determine the association between a steep increase in 
FBG from midlife to late life (slope ≥ 2.0 mg/dL/y) compared with non-steep increase 




age 55 years) and Exam 7 represented late life (mean age 69 years). Exam 7 was used as 
baseline (time zero).  
Sensitivity analyses were performed according to a different set of covariate-
adjusted, multiple-variable Cox regression models. Model 1 adjusted for the variables of 
age and sex/gender. Model 2 additionally adjusted for education, APOE4 carrier state, 
and prevalent CVD. Model 3 adjusted for age, sex, education, APOE4, prevalent CVD, 
and midlife T2DM treatment. Interaction analysis was also performed between steep 
increase FBG and APOE4 carriers, followed by stratified (subgroup) analyses according 
to the different APOE4 carrier status. For all analyses, statistical significance was 






Table 2 summarizes the baseline characteristics of the 1287 Framingham 
Offspring Study participants in this study. The mean age of participants at Exam 7 was 
68.6 ± 5.7 years, and the number of females (n = 669) was 52% of the total participants. 
Complete data on FBG during Exams 3-7 were obtained on these subjects. During a 
mean follow-up period of 14 ± 4.5 years, 172 (13%) participants were diagnosed with 
dementia and 135 (10%) were diagnosed with AD.  
 
Table 2 
Baseline Characteristics of Participants 
Characteristic                                                                                              Participants 
(n = 1287) 
Female sex, n (%) 669 (52%) 
Age, mean ± SD, y 68.6 ± 5.7 
Education, n (%)  
No high school degree 64/1,061 (6%) 
High school degree 309/1,061 (29%) 
Some years of college 311/1,061 (29%) 
College degree 377/1,061 (36%) 
APOE4 allele, n (%)  
Non-carriers 997 (77%) 
Carriers 272 (21%) 
Missing 18 (1.4%) 
Characteristic                                                                                              Participants  




Prevalent CVD, n (%)  
No 1109 (86%) 
Yes 178 (3%) 
T2DM 196/1,287 (15%) 
Treatment for T2DM 119/1,286 (9%) 
Atrial fibrillation 84/1,287 (7%) 
Current smoking 104/1,287 (8%) 
Antihypertensive medication  
No 708/1,287 (55%) 
Yes 579/1,287 (45%) 
Midlife diabetic measurements  
FBG, mean ± SD, mg/dL  96 ± 22.4 
T2DM 57/1,287 (4%) 
Treatment for T2DM 22/1,287 (2%) 
Late-life diabetic measurements  
FBG, mean ± SD, mg/dL 110 ± 27.8 
T2DM 196/1,287 (15%) 
Treatment for T2DM 119/1,286 (9%) 
Midlife to late-life trajectory of diabetic measurements, n (%)  
Persistent high FBG 152/1,286 (12%) 
Steep increase in FBG 155/1,286 (12%) 
 
Note. This table shows the baseline demographics and clinical characteristics of participants that were 
defined at Exam 7. Persistent high FBG was defined as any two measurements ≥ 126 mg/dL of five FBG 
measurements from Exam 3 to Exam 7. Steep increase in FBG was based on a cutoff score of slope 2 
mg/dL per year (a steep increase in FBG during midlife to late life). APOE4 = apolipoprotein E4 ; CVD = 





In Figure 2, a Kaplan-Meier (K-M) Plot portrays the probability that participants do not 
develop AD (defined as AD-free probability) for up to 18 years follow-up after Exam 7. 
As shown in the figure, participants who had a steep increase in FBG (“Yes”) had a lower 
probability of not developing AD. Participants who did not have a steep increase in FBG 
(“No”) were less likely to develop AD. Exam 7 was used as the baseline (time zero), 
including a total of 1287 participants. As time passed, the number of participants at risk 
to be AD-free decreased in both groups (i.e. the number of participants at risk for 
developing AD increased in both groups). This is likely attributed to the fact that the risk 






















Note. The Kaplan-Meier (K-M) plot shows the steep increase in FBG associated with incident 
Alzheimer’s disease (AD) up to 18 years follow-up. AD-free probability refers to the probability 
of an individual not developing AD. The steep increase in FBG was based on a cutoff score of 
slope 2 mg/dL per year (a steep increase in fasting glucose during midlife to late life). No = no 
steep increase in FBG; Yes = steep increase in FBG. The K-M plot shows that individuals with a 
steep increase in FBG had a lower probability of not developing AD. Exam 3 represented midlife 
(mean age 55 years); Exam 7 represented late life (mean age 69 years); Exam 7 was used as 





Midlife T2DM and FBG Effects on Incident Dementia and AD 
Multivariable Cox proportional hazards models showed that T2DM during 
midlife was not significantly associated with an increased risk of incident dementia or 
AD (see Table 3). However, there was an increased risk of incident dementia and AD 
during midlife associated with each 10-mg/dL increment increase in FBG. When adjusted 
for age and sex (Model 1), there was an increase in risk of incident dementia ([HR] 1.06, 
95% [CI] 1.01-1.12; p value < 0.05) and an increased risk for AD ([HR] 1.07, 95% [CI] 
1.02-1.13; p value < 0.01). When adjusted for age, sex, education, APOE4, and prevalent 
CVD (Model 2), there was an increase in risk of incident dementia ([HR] 1.10, 95% [CI] 
1.03-1.18; p value < 0.01) and an increased risk for AD ([HR] 1.12, 95% [CI] 1.04-1.20; 
p value < 0.01). When adjusted for age, sex, education, APOE4, prevalent CVD, and 
midlife T2DM treatment (Model 3), there was an increase in risk of incident dementia 
([HR] 1.12, 95% [CI] 1.04-1.20; p value < 0.01) and an increased risk for AD ([HR] 1.12, 
95% [CI] 1.04-1.21; p value < 0.01). 
 
Late-Life T2DM and FBG Effects on Incident Dementia and AD 
Multivariable Cox proportional hazards models showed that T2DM during late 
life was significantly associated with an increased risk of incident dementia ([HR] 1.51, 
95% [CI] 1.02-2.22; p value < 0.05) and AD ([HR] 1.69, 95% [CI] 1.10-2.60; p value < 
0.05) when adjusted for age and sex (Model 1) (see Table 3). There was also an increased 
risk of incident dementia and AD during late life associated with each 10–mg/dL 




increase in risk of incident dementia ([HR] 1.07, 95% [CI] 1.02-1.12; p value < 0.01) and 
an increased risk for AD ([HR] 1.09, 95% [CI] 1.04-1.15; p value < 0.001). When 
adjusted for age, sex, education, APOE4, and prevalent CVD (Model 2), there was an 
increase in risk of incident dementia ([HR] 1.08, 95% [CI] 1.03-1.13; p value < 0.01) and 
an increased risk for AD ([HR] 1.08, 95% [CI] 1.03-1.14; p value < 0.01). When adjusted 
for age, sex, education, APOE4, prevalent CVD, and midlife T2DM treatment (Model 3), 
there was an increase in risk of incident dementia ([HR] 1.08, 95% [CI] 1.03-1.13; p 
value < 0.05) and an increased risk for AD ([HR] 1.08, 95% [CI] 1.02-1.14; p value < 
0.01). 
 
Persistent High FBG During Midlife to Late Life 
Persistent high fasting blood glucose was defined as any two measurements ≥ 126 
mg/dL of five fasting blood glucose measurements from Exam 3 to Exam 7. 
Multivariable Cox proportional hazards models showed a 2-fold increased risk of 
incident dementia and AD associated with persistent high FBG in all models (see Table 
3). When adjusted for age and sex (Model 1), there was an increase in risk of incident 
dementia ([HR] 2.15, 95% [CI] 1.45-3.19; p value < 0.001) and an increased risk for AD 
([HR] 2.43, 95% [CI] 1.58-3.76; p value < 0.001). When adjusted for age, sex, education, 
APOE4, and prevalent CVD (Model 2), there was an increase in risk of incident dementia 
([HR] 2.07, 95% [CI] 1.34-3.19; p value < 0.001) and an increased risk for AD ([HR] 
2.17, 95% [CI] 1.35-3.50; p value < 0.001). When adjusted for age, sex, education, 




in risk of incident dementia ([HR] 2.13, 95% [CI] 1.37-3.33; p value < 0.001) and an 
increased risk for AD ([HR] 2.18, 95% [CI] 1.33-3.57; p value < 0.001). 
 
Steep Increase in FBG During Midlife to Late Life 
Steep increase in FBG was based on a cutoff score of slope 2 mg/dL per year (a 
steep increase in fasting glucose during midlife to late life). Multivariable Cox 
proportional hazards models showed an increased risk of incident dementia and AD 
associated with a steep increase in FBG during midlife to late life in most of the models 
(see Table 3). When adjusted for age and sex (Model 1), there was an increase in risk for 
AD ([HR] 1.78, 95% [CI] 1.13-2.82; p value < 0.05). When adjusted for age, sex, 
education, APOE4, and prevalent CVD (Model 2), there was an increase in risk of 
incident dementia ([HR] 1.60, 95% [CI] 1.02-2.51; p value < 0.05) and an increased risk 
for AD ([HR] 1.72, 95% [CI] 1.05-2.82; p value < 0.05). When adjusted for age, sex, 
education, APOE4, prevalent CVD, and midlife T2DM treatment (Model 3), there was an 
increase in risk of incident dementia ([HR] 1.59, 95% [CI] 1.01-2.51; p value < 0.05) and 











Fasting Blood Glucose From Midlife to Late Life and Dementia/Alzheimer’s Disease 
 Dementia, HR (95% CI) AD, HR (95% CI) 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Midlife       
T2DM 1.43  (0.75-2.74) 
1.48  
(0.73-3.00) 



















Late life       

























Midlife to late 
life trajectory 






























Note. Table 3 includes the results of the multivariable cox proportional hazards models for the 
risk of developing dementia and AD during midlife and late life. Persistent high fasting blood 
glucose (FBG) is defined as any two measurements ≥ 126 mg/dL of five fasting blood glucose 
measurements from Exam 3 to Exam 7. Exam 3 represents midlife (mean age 55 years); Exam 7 
represents late life (mean age 69 years). Steep increase in FBG is based on a cutoff score of slope 
2 mg/dL per year (a steep increase in fasting glucose during midlife to late life). Model 1 adjusts 
for age and sex. Model 2 adjusts for age, sex, education, apolipoprotein E4 (APOE4), and 
prevalent cardiovascular disease (CVD). Model 3 adjusts for age, sex, education, APOE4, 
prevalent CVD, and midlife T2DM treatment. Blank cells indicate insufficient sample size to 
complete the analysis. AD = Alzheimer’s disease; CI = confidence interval; FBG= fasting blood 





Subgroup Analysis: Steep Increase in FBG Associated With APOE4 Carrier Status 
In a subgroup analysis, an evaluation was performed to determine whether there 
was an interaction effect between a steep increase in FBG and APOE4 allele carrier status 
for developing incident dementia or AD. As seen in Table 4, an APOE4 non-carrier with 
a steep increase in FBG was associated with an approximate 2-fold increased risk for 
developing incident dementia ([HR] 1.90, 95% [CI] 1.12-3.16; p value < 0.05) and AD 
([HR] 2.30, 95% [CI] 1.28-4.06; p value < 0.05). Alternatively, for an APOE4 carrier 
with a steep increase in FBG, there were no significant effects for developing incident 
dementia ([HR] 0.75, 95% [CI] 0.27-2.07; p value > 0.05) or AD ([HR] 0.71, 95% [CI] 
0.25-2.02; p value > 0.05). 
 
Table 4 




HR (95% CI) P 
value 















Note. This table shows the multivariable cox proportional hazards model for the interaction effect between 
a steep increase in FBG and APOE4 carrier status. AD = Alzheimer’s disease ; APOE4 = apolipoprotein 





Table 5 shows that both the main effects of FBG slope ≥ 2 mg/dL per year ([HR] 
2.12, 95% [CI] 1.19-3.76; p = 0.01) and APOE4 carriers ([HR] 3.56, 95% [CI] 2.3-5.38; 
p < 0.001) significantly increase the risk for developing AD. The interaction item 
(interaction of FBG slope ≥ 2 mg/dL per year & APOE4 carriers) shows there might be a 
revised trend ([HR] 0.49, 95% [CI] 0.16-1.50; p = 0.21) for APOE4 carriers; however, 
the trend does not have statistical significance (p = 0.21). 
Table 5 
Association Between Steep Increasing FBG and AD Onset 
 HR (95% CI) P value 
FBG slope ≥ 2 mg/dL per year 2.12 (1.19-3.76) 0.01 
APOE4 carriers 3.56 (2.3-5.38) < 0.001 
Interaction of  
FBG slope ≥ 2 mg/dL per year & APOE4 carriers 0.49 (0.16-1.50) 0.21 
Sex: Female 1.92 (1.27-2.92) < 0.01 
Age (years) 1.17 (1.14-1.21) < 0.001 
Education: High school 0.53 (0.28-0.98 0.04 
Education: Some college 0.53 (0.29-0.99) 0.05 
Education: College 0.37 (0.19-0.71) 0.00 
CVD 1.21 (0.73-1.99) 0.46 
Midlife T2DM treatment 1.53 (0.37-6.37) 0.56 
Note. This table shows the interaction between a steep increase in FBG (defined as ≥ 
2 mg/dL per year) and APOE4 carrier status and the onset of AD. AD = 
Alzheimer’s disease; APOE4= apolipoprotein E4; CVD= cardiovascular disease; 









T2DM and AD used to be thought of as independent disorders. More recently, an 
increasing amount of evidence has supported a close association between T2DM and 
neurodegenerative disorders such as AD. This follow-up study on the Framingham Heart 
Study community-based cohort supports previous findings that T2DM is associated with 
cognitive deficits and dementia. The data in this study showed that participants were at 
highest risk (>2-fold increase) for developing incident dementia and AD when they had 
persistent high FBG from midlife to late life. This paper therefore supports the need for 
interventional strategies, such as weight loss and aggressive glucose management, to be 
initiated during midlife rather than late life. 
Although it is now widely recognized that insulin metabolism and signaling can 
contribute to neurodegeneration, as seen in AD and other dementias, the underlying 
mechanisms remain obscure (Tumminia et al., 2018). T2DM and AD show similar 
pathologies, including impaired insulin signaling, increased oxidative stress, increased 
Aβ production, neurofibrillary tangles, and cerebrovascular issues (Ahn et al., 2019). 
Comorbid T2DM can also worsen clinical symptoms of patients with either AD or other 
dementias (Li & Huang, 2016). Research suggests that treatment of diabetic 
complications with several anti-diabetic medications may help alleviate these 
pathologies, as evidenced by prolonged lifespan, reduction of Aβ plaques, and 
improvement of cognitive function. In a previous study, the combined use of insulin and 




assessed brain regions, suggesting a potentially therapeutic effect on AD pathology 
(Bendlin, 2019). Although some antidiabetic medications show therapeutic potential in 
treating AD, more detailed knowledge on common pathologies between T2DM and AD, 
molecular action of drugs both centrally and peripherally in the body, influence of 
demographic changes and genetic mutations on AD progression are needed to confidently 
decide the best treatment options (Jayaraj et al., 2020). 
Previous research has also found that HbA1c, a measure of average blood glucose 
level, is associated with the risk of dementia and cognitive impairment (Rawlings et al., 
2017). However, the role of blood glucose level variability in this association is unclear. 
After examining the effects of glucose peaks in midlife with the risk of dementia, the 
investigators found that these peaks were associated with cognitive decline. Among 
participants with T2DM and HbA1c ≥ 7% (53 mmol/mol), those with glucose peaks had 
a 0.38 greater z-score (standard score) decline compared with persons without glucose 
peaks (p < 0.001). This is consistent with the results of this study in that sharp increases 
in blood glucose levels were detrimental to long-term cognitive function. In addition to 
primary prevention of T2DM as a tool for preventing dementia, these results suggest that 
preventing sharp increases in blood glucose levels could also prove therapeutic in 
preventing cognitive decline. 
 The results of this study also highlight a target for prevention in educating the 
public on the importance of maintaining healthy blood glucose levels. A more aggressive 
approach to monitoring blood glucose levels and identifying prediabetes at an earlier 




and thus decreasing the chance for developing AD and other forms of dementia later on 
in life. However, it is important to note that not all studies to date demonstrate the 
relationship between impaired glucose regulation and cognitive dysfunction. T2DM alone 
cannot be assumed to be sufficient to cause AD, but could be considered to serve as one 
cofactor in AD progression due to selective impairments in insulin signaling along with 
significant increases in Aβ aggregation, tau hyperphosphorylation, inflammation, 
oxidative stress and mitochondrial dysfunction (Jayaraj et al., 2020). Preventing T2DM is 
just one of many potentially therapeutic tools in decreasing the risk of cognitive 
impairment later in life. 
 
APOE4 Allele and T2DM 
Previous studies have strongly supported that APOE4 increases the risk for 
developing AD and incident dementia (Theendakara et al., 2018).  Nevertheless, the 
mechanism underlying their interaction has yet to be identified. In one particular study, a 
model of APOE4-targeted replacement mice and high-fat diet (HFD)-induced insulin 
resistance was utilized to investigate diabetic mechanisms associated with APOE4  
pathology and the extent to which they are driven by peripheral and central processes 
(Koren-Iton et al., 2020). The results showed that under basal conditions, APOE4 mice 
display impaired glucose and insulin tolerance and decreased insulin secretion, as well as 
cognitive and sensorimotor characteristics relative to APOE3 mice, whereas the HFD 
impairs APOE3 mice without significantly affecting APOE4 mice. These data suggest 




APOE4. Consequently, diabetic-related therapy may be useful in treating APOE4 
pathology in AD. The results in this study found that non-APOE4 allele carriers had an 
increased risk of developing incident dementia and AD when they had a steep increase in 
FBG levels (Table 3). Although the results showed that there was no significant added 
risk for developing incident dementia in participants with an APOE4 allele carrier and a 




This study has some limitations that should be considered when interpreting the 
results, including a high racial homogeneity of non-Hispanic White participants in the 
FHS, and as a result, the findings may not be generalizable to other races. In addition, the 
diagnosis of dementia and AD are clinical diagnoses rather than biomarker-based 
determinations, which would increase the diagnostic accuracy. Another limitation is that 
the mean follow-up time of ten years may not be long enough. There would likely be 
more outcome events if participants were followed up at a longer time. Lastly, the FHS 
sample size in the APOE4 group is very small (the proportion for APOE4 carriers is 
22%); therefore, there may not have been sufficient power. Further research 
incorporating a larger sample size is necessary for determining if there is an interaction 






Implications for Future Research 
A conclusion regarding the link between T2DM and cognitive decline is difficult 
to reach because studies generally suffer from methodological problems that include 
small sample sizes, heterogeneous populations, different batteries of tests, and failure to 
control for major confounding factors such as age and education. Where confounders are 
concerned, controlling for APOE4 carrier status—a known risk factor for AD—did not 
alter the age-, sex-, and education-adjusted results. This suggests that the relationship 
may actually depend on the diabetic state itself. Another major challenge for researchers 
is being able to pinpoint the specific diabetes-related disease processes that affect the 
brain and contribute to development of dementia beyond the pathologies of AD. 
Observations from experimental models are needed to ascertain this information. 
Timing of interventions is also of concern in relation to disease course. The onset 
of AD symptoms is usually long after pathologies have begun to accumulate, such as Aβ 
plaques and neurofibrillary tangles. Mitigating risk factors of pathology should likely 
include treating individuals early, prior to the development of pathologies, for maximum 
effectiveness. Researchers are interested in further investigating treatments that target the 
MCI stage because individuals in this stage are still able to function independently and 
the pathologies of the disease are not as advanced (Gaugler et al., 2021).  
Identifying biomarkers at an earlier stage can help with diagnosing cognitive 
impairment and could serve as therapeutic targets. The biomarkers of cognitive decline in 
people with T2DM can be classified into three categories: serum molecules or relevant 




variants (Zhao et al., 2017). Specifically, factors related to impaired glucose metabolism, 
IR, inflammation, micro-/microvasculature complications, adipokines, neurotrophic 
molecules and tau proteins are significantly altered in diabetic patients with cognitive 
decline. Thus, biomarker tests, such as PET brain imaging and protein analysis of blood 
and CSF, can help prevent late-stage diagnosis of AD and prevent metabolic disease 
induced AD progression (Gaugler et al., 2021; Jayaraj et al., 2020).  
 Since AD may begin 20 years before the onset of symptoms, this large, critical 
window of time has become the interest of researchers to intervene in the progression of 
the disease. Development of a therapy that could prevent MCI from progressing to more 
advanced stages would significantly improve an individual’s quality of life and decrease 
health care costs and spending. 
Improving the diversity of participants in future studies so that the results are 
more applicable to the general population is a critical step in advancing the understanding 
of AD. Most of the research to date has not included sufficient numbers of Blacks, 
Hispanics, Asian Americans/Pacific Islanders, and Native Americans to be representative 
of the United States population (Gaugler et al., 2021). Because Blacks and Hispanics are 
at increased risk for AD, their underrepresentation hinders research from understanding 
factors that may contribute to their increased risk. With improved representation in 
clinical trials, a wider population will have the potential to benefit from advances in AD. 
The lack of an effective treatment for AD and other dementias creates a 
substantial interest in identifying potentially modifiable risk factors. A better 




possibilities for prevention of age-related cognitive decline and address the major public 
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